
http://eprints.gla.ac.uk/17118/

Deposited on: 19 January 2012
Response to Letter by Proctor and Tamborello
Kennedy R. Lees, Tim Ashwood and Tomas Odergren

Stroke 2007, 38:e110: originally published online August 23, 2007
doi: 10.1161/STROKEAHA.107.493411
Stroke is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2007 American Heart Association. All rights reserved. Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/38/10/e110

Subscriptions: Information about subscribing to Stroke is online at http://stroke.ahajournals.org/subscriptions/

Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. Fax: 410-528-8550. E-mail: journalpermissions@lww.com

Reprints: Information about reprints can be found online at http://www.lww.com/reprints
Response to Letter by Proctor and Tamborello

Response

It is premature to comment on SAINT II before any manuscript is published. However, the suggestion that different products were used for the 2 SAINT trials can be discounted. Relevant knowledge contained in the patent application was applied identically to the study drug supplied for SAINT I and II. The patent application for test article preparation was filed in Sweden in May 2000 and filed internationally in May 2001. SAINT I commenced in April 2003. The suggestion that the SAINT I trial may have been delayed pending animal toxicity tests is also untrue. Appropriate testing was completed before early phase trials. The SAINT I protocol was finalized in December 2002, after the last of the preclinical efficacy studies advised by STAIR guidelines had concluded.1,2 Recruitment to SAINT I started promptly after Institutional Review Board and regulatory approvals, in April 2003, and completed ahead of schedule.3,4 Recruitment into SAINT II was impaired for a while in the US because of an interim restriction on the protocol barring concomitant treatment with rt-PA pending completion of the FDA requested interaction data.

Disclosures

K.R.L. received fees, expenses, and institutional investigator fees for steering committee work and trial participation from AstraZeneca. T.A. and T.O. are employees of AstraZeneca.

Kennedy R. Lees, MD, FRCP
University Department of Medicine & Therapeutics
Gardiner Institute
Western Infirmary
Glasgow, UK

Tim Ashwood, PhD
AstraZeneca R&D
Medical Neuroscience
Södertälje, Sweden

Tomas Odergren, MD
Vice President, Global Product Director NXY-059
AstraZeneca R&D
Södertälje, Sweden


© 2007 American Heart Association, Inc.

Stoke is available at http://stroke.ahajournals.org

DOI: 10.1161/STROKEAHA.107.493411

Downloaded from http://stroke.ahajournals.org on January 19, 2012